This was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, efficacy and therapeutic dose range of MK-7264 for the treatment of chronic cough; overall, 253 patients from the United States and the United Kingdom were included in the study. Cough frequency was measured using the Vitalograph VitaloJAK device.
- Author Smith J. et al
- Publication American Journal of Respiratory and Critical Care Medicine
- Year 2017
- Device Type VitaloJAK